CA3117550A1 - 1,3,4-oxadiazolone compound and pharmaceutical - Google Patents
1,3,4-oxadiazolone compound and pharmaceutical Download PDFInfo
- Publication number
- CA3117550A1 CA3117550A1 CA3117550A CA3117550A CA3117550A1 CA 3117550 A1 CA3117550 A1 CA 3117550A1 CA 3117550 A CA3117550 A CA 3117550A CA 3117550 A CA3117550 A CA 3117550A CA 3117550 A1 CA3117550 A1 CA 3117550A1
- Authority
- CA
- Canada
- Prior art keywords
- oxadiazol
- amino
- trifluoromethyl
- pheny1
- piperidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018214950 | 2018-11-15 | ||
| JP2018-214950 | 2018-11-15 | ||
| PCT/JP2019/044615 WO2020100959A1 (ja) | 2018-11-15 | 2019-11-14 | １，３，４－オキサジアゾロン化合物及び医薬 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3117550A1 true CA3117550A1 (en) | 2020-05-22 |
Family
ID=70731909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3117550A Pending CA3117550A1 (en) | 2018-11-15 | 2019-11-14 | 1,3,4-oxadiazolone compound and pharmaceutical |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20220024921A1 (https=) |
| EP (1) | EP3882239A4 (https=) |
| JP (1) | JP7434172B2 (https=) |
| KR (1) | KR20210091767A (https=) |
| CN (1) | CN113302184B (https=) |
| AU (1) | AU2019381493B2 (https=) |
| BR (1) | BR112021009198A2 (https=) |
| CA (1) | CA3117550A1 (https=) |
| CL (1) | CL2021001275A1 (https=) |
| CO (1) | CO2021007442A2 (https=) |
| EA (1) | EA202191349A1 (https=) |
| EC (1) | ECSP21034281A (https=) |
| IL (1) | IL282999A (https=) |
| MA (1) | MA54243A (https=) |
| MX (1) | MX2021005566A (https=) |
| PE (1) | PE20211283A1 (https=) |
| PH (1) | PH12021551103A1 (https=) |
| SA (1) | SA521421997B1 (https=) |
| SG (1) | SG11202104371XA (https=) |
| TW (1) | TWI840448B (https=) |
| UA (1) | UA129949C2 (https=) |
| WO (1) | WO2020100959A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4516778A4 (en) | 2022-04-25 | 2026-04-29 | Nippon Shinyaku Co Ltd | COMPOUND SERVING AS A DDR1 KINASE INHIBITOR AND MEDICINE |
| CN117285459B (zh) * | 2023-11-24 | 2024-02-27 | 上海美迪西生物医药股份有限公司 | 一种小分子激酶抑制剂化合物的制备方法 |
| CN118515653B (zh) * | 2024-07-23 | 2024-12-10 | 西湖制药(杭州)有限公司 | 一种ezh2特异性抑制剂及其制备方法和用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01139581A (ja) * | 1987-08-20 | 1989-06-01 | Nissan Chem Ind Ltd | テトラヒドロフタルイミド誘導体、その製法および除草剤 |
| TW200526626A (en) * | 2003-09-13 | 2005-08-16 | Astrazeneca Ab | Chemical compounds |
| EP1797040A1 (en) | 2004-09-29 | 2007-06-20 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
| CA2591738A1 (en) | 2004-12-22 | 2006-06-29 | Merck & Co., Inc. | Process for making substituted piperidines |
| JP2011515337A (ja) | 2008-02-29 | 2011-05-19 | サイレーン ファーマシューティカルズ， インコーポレイテッド | プロテインキナーゼモジュレーター |
| GB0813740D0 (en) | 2008-07-28 | 2008-09-03 | Angeletti P Ist Richerche Biologica | Therapeutic compounds |
| TWI496779B (zh) | 2008-08-19 | 2015-08-21 | Array Biopharma Inc | 作為ｐｉｍ激酶抑制劑之三唑吡啶化合物 |
| CA2819373A1 (en) * | 2010-12-09 | 2012-06-14 | Amgen Inc. | Bicyclic compounds as pim inhibitors |
| JP2014510105A (ja) | 2011-03-22 | 2014-04-24 | アムジエン・インコーポレーテツド | Ｐｉｍ阻害剤としてのアゾール化合物 |
| WO2013007765A1 (en) | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Fused tricyclic compounds for use as inhibitors of janus kinases |
| CN104540830A (zh) | 2012-06-07 | 2015-04-22 | 霍夫曼-拉罗奇有限公司 | 端锚聚合酶的吡唑并嘧啶酮和吡唑并吡啶酮抑制剂 |
| GB201814151D0 (en) | 2018-08-31 | 2018-10-17 | Ucl Business Plc | Compounds |
-
2019
- 2019-11-14 EA EA202191349A patent/EA202191349A1/ru unknown
- 2019-11-14 WO PCT/JP2019/044615 patent/WO2020100959A1/ja not_active Ceased
- 2019-11-14 CN CN201980089037.7A patent/CN113302184B/zh active Active
- 2019-11-14 BR BR112021009198-0A patent/BR112021009198A2/pt unknown
- 2019-11-14 AU AU2019381493A patent/AU2019381493B2/en active Active
- 2019-11-14 KR KR1020217017903A patent/KR20210091767A/ko active Pending
- 2019-11-14 MX MX2021005566A patent/MX2021005566A/es unknown
- 2019-11-14 PE PE2021000693A patent/PE20211283A1/es unknown
- 2019-11-14 MA MA054243A patent/MA54243A/fr unknown
- 2019-11-14 US US17/293,929 patent/US20220024921A1/en active Pending
- 2019-11-14 CA CA3117550A patent/CA3117550A1/en active Pending
- 2019-11-14 SG SG11202104371XA patent/SG11202104371XA/en unknown
- 2019-11-14 EP EP19883405.3A patent/EP3882239A4/en not_active Withdrawn
- 2019-11-14 JP JP2020556150A patent/JP7434172B2/ja active Active
- 2019-11-14 UA UAA202103273A patent/UA129949C2/uk unknown
- 2019-11-15 TW TW108141565A patent/TWI840448B/zh active
-
2021
- 2021-05-06 IL IL282999A patent/IL282999A/en unknown
- 2021-05-10 SA SA521421997A patent/SA521421997B1/ar unknown
- 2021-05-14 CL CL2021001275A patent/CL2021001275A1/es unknown
- 2021-05-14 PH PH12021551103A patent/PH12021551103A1/en unknown
- 2021-05-14 EC ECSENADI202134281A patent/ECSP21034281A/es unknown
- 2021-06-08 CO CONC2021/0007442A patent/CO2021007442A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019381493B2 (en) | 2024-10-31 |
| SA521421997B1 (ar) | 2025-04-10 |
| JP7434172B2 (ja) | 2024-02-20 |
| PH12021551103A1 (en) | 2021-11-22 |
| CL2021001275A1 (es) | 2021-11-05 |
| JPWO2020100959A1 (ja) | 2021-10-07 |
| ECSP21034281A (es) | 2021-06-30 |
| PE20211283A1 (es) | 2021-07-19 |
| EP3882239A1 (en) | 2021-09-22 |
| US20220024921A1 (en) | 2022-01-27 |
| MA54243A (fr) | 2021-09-22 |
| AU2019381493A1 (en) | 2021-06-03 |
| CN113302184B (zh) | 2024-11-22 |
| TWI840448B (zh) | 2024-05-01 |
| UA129949C2 (uk) | 2025-09-24 |
| TW202031649A (zh) | 2020-09-01 |
| KR20210091767A (ko) | 2021-07-22 |
| WO2020100959A1 (ja) | 2020-05-22 |
| EP3882239A4 (en) | 2022-08-10 |
| IL282999A (en) | 2021-06-30 |
| CN113302184A (zh) | 2021-08-24 |
| SG11202104371XA (en) | 2021-05-28 |
| EA202191349A1 (ru) | 2021-08-10 |
| CO2021007442A2 (es) | 2021-06-21 |
| MX2021005566A (es) | 2021-07-15 |
| BR112021009198A2 (pt) | 2021-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6160613B2 (ja) | Ｔｒｋ阻害化合物 | |
| USRE46886E1 (en) | Alkoxy pyrazoles as soluble guanylate cyclase activators | |
| KR102682216B1 (ko) | 칸나비노이드 수용체 조절제 | |
| CN102666489B (zh) | 鞘氨醇激酶抑制剂 | |
| JP6689297B2 (ja) | 複素環化合物 | |
| JPWO2012036278A1 (ja) | グリシントランスポーター阻害物質 | |
| CA3117550A1 (en) | 1,3,4-oxadiazolone compound and pharmaceutical | |
| CN102639513A (zh) | 鞘氨醇激酶抑制剂 | |
| KR20230051125A (ko) | Bcl-2 억제제로서의 화합물 | |
| HK40051017A (en) | 1,3,4-oxadiazolone compound and medicine | |
| WO2023060173A1 (en) | Compounds, compositions and methods of use | |
| HK40051487B (zh) | 1,3,4-恶二唑啉酮化合物和药物 | |
| JP2025526321A (ja) | Ｔｅａｄ阻害薬および使用方法 | |
| KR20260053336A (ko) | Erk의 활성 조절을 위한 화합물 및 조성물 | |
| EP4676476A1 (en) | Inhibitors of tdp-43 and tau aggregation | |
| WO2012081665A1 (ja) | グリシントランスポーター阻害物質 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20231110 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20241122 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250318 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250327 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250715 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250715 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250929 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250929 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D149 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S INTERVIEW Effective date: 20251124 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260122 |